NovoCure (NASDAQ:NVCR) Issues Earnings Results, Beats Estimates By $0.20 EPS

NovoCure (NASDAQ:NVCR) announced its quarterly earnings results on Thursday. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.20, FiscalAI reports. NovoCure had a negative return on equity of 44.02% and a negative net margin of 21.25%.The business had revenue of $183.58 million for the quarter, compared to analyst estimates of $172.44 million. During the same quarter in the prior year, the company earned ($0.36) earnings per share. The company’s quarterly revenue was up 15.6% on a year-over-year basis.

Here are the key takeaways from NovoCure’s conference call:

• NovoCure posted its strongest commercial quarter to date, with Q2 revenue of $184 million up 16% year over year and adjusted EBITDA turning positive at $11 million.
• Optune Gio remained the core growth driver, ending the quarter with 4,636 active patients on therapy, up 11% year over year, with particularly strong growth in the U.S., Germany, Japan, and global markets.
• Optune Pax launch momentum continued in locally advanced pancreatic cancer, with 418 prescriptions and 285 patients on therapy at quarter-end; management said adoption is broadening across community and academic sites and repeat prescribing is increasing.
• Management received CE Mark for Optune Pax in Europe and has begun Germany labeling, registration, and prescriber certification, but expects reimbursement and hospital contracting to make the ramp slower than in the U.S.
• The company raised full-year guidance to $710 million-$725 million in revenue and $0-$15 million in adjusted EBITDA, while also saying it now expects to reach full-year 2026 adjusted EBITDA breakeven.
• NovoCure is refocusing R&D around pancreatic cancer and broader label expansion, including an upcoming IDE trial with divarasib/RAS inhibitors, while trimming LUNAR-2 spend by about $90 million to support profitability goals.

NovoCure Stock Performance

NASDAQ NVCR opened at $17.65 on Friday. The company has a market capitalization of $2.04 billion, a PE ratio of -13.58 and a beta of 0.94. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.70 and a current ratio of 2.90. NovoCure has a 52-week low of $9.82 and a 52-week high of $21.45. The company has a 50-day simple moving average of $16.64 and a 200 day simple moving average of $14.14.

Insider Transactions at NovoCure

In other NovoCure news, Director W Anthony Vernon sold 2,945 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $15.77, for a total value of $46,442.65. Following the transaction, the director directly owned 197,657 shares in the company, valued at $3,117,050.89. The trade was a 1.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Allyson J. Ocean sold 2,945 shares of the stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $15.77, for a total value of $46,442.65. Following the transaction, the director directly owned 11,324 shares of the company’s stock, valued at approximately $178,579.48. This trade represents a 20.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 51,943 shares of company stock valued at $893,171. Corporate insiders own 5.52% of the company’s stock.

Institutional Investors Weigh In On NovoCure

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Alliancebernstein L.P. raised its holdings in shares of NovoCure by 0.8% in the 3rd quarter. Alliancebernstein L.P. now owns 137,106 shares of the medical equipment provider’s stock valued at $1,771,000 after acquiring an additional 1,076 shares in the last quarter. Royal Bank of Canada grew its holdings in shares of NovoCure by 14.9% during the fourth quarter. Royal Bank of Canada now owns 12,830 shares of the medical equipment provider’s stock worth $166,000 after purchasing an additional 1,667 shares in the last quarter. LPL Financial LLC grew its holdings in shares of NovoCure by 15.1% during the fourth quarter. LPL Financial LLC now owns 16,380 shares of the medical equipment provider’s stock worth $212,000 after purchasing an additional 2,153 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of NovoCure by 3.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,992 shares of the medical equipment provider’s stock worth $1,336,000 after buying an additional 2,502 shares during the last quarter. Finally, Empowered Funds LLC purchased a new stake in NovoCure during the fourth quarter valued at about $33,000. Hedge funds and other institutional investors own 84.61% of the company’s stock.

Key NovoCure News

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: NovoCure reported Q2 EPS of -$0.13, beating the consensus loss estimate of -$0.33, while revenue came in at $183.6 million versus expectations of $172.4 million. Revenue also rose 15.6% year over year, signaling improving business momentum.
• Positive Sentiment: The company raised its FY2026 revenue guidance to $710 million-$725 million, above the market’s prior expectation of about $704 million, which suggests management sees continued demand strength.
• Positive Sentiment: HC Wainwright increased its price target on NovoCure to $52 from $46 and maintained a Buy rating, reinforcing optimism around the company’s longer-term earnings potential. Article Title
• Neutral Sentiment: Wedbush also raised its price target to $20 from $18, but kept a Neutral rating, indicating improved expectations without a strong bullish call. Article Title
• Neutral Sentiment: Shares also got a lift from optimism around the company’s brain therapy pipeline and possible FDA-related catalysts, which helped push the stock to new highs as investors priced in further upside. Article Title
• Negative Sentiment: HC Wainwright trimmed its FY2029 EPS estimate slightly to $1.90 from $1.95, a small caution on the company’s very long-term earnings outlook.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Zacks Research downgraded shares of NovoCure from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Wells Fargo & Company raised their price target on shares of NovoCure from $13.50 to $17.00 and gave the company an “equal weight” rating in a research report on Monday, May 4th. Wedbush lifted their price target on NovoCure from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Friday. Evercore reiterated an “outperform” rating on shares of NovoCure in a report on Friday, May 1st. Finally, HC Wainwright set a $32.00 price target on shares of NovoCure in a research report on Friday. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, NovoCure has a consensus rating of “Hold” and a consensus price target of $21.20.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.